Public health innovation: Biopharmaceuticals lost in translation?

Therapeutic Innovation and Regulatory Science

Volumn 47, Issue 3, 2013, Pages 306-311

  Halim, Nader D ^a   Doyle, John J ^a,b  

^a IQVIA   (United States)

^b Department of Medicine   (United States)

Author keywords

Biopharmaceuticals; Drug development; Public health innovation

Indexed keywords

ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PHARMACY; FUNDING; HUMAN; MEDICAL RESEARCH; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESOURCE ALLOCATION;

EID: 84878787083     PISSN: 21684790     EISSN: 21649200     Source Type: Journal    
DOI: 10.1177/2168479013482315     Document Type: Article

References (14)

1. Shiffman J. Donor funding priorities for communicable disease control in the developing world. Health Policy Plan. 2006; 21(6):411-420. doi:10.1093/heapol/czl028
2. Croghan W, Pittman P. The medicine cabinet: what's in it, why, and can we change the contents? Health Aff (Millwood). 2004; 23(1):23-33
3. World Health Organization. Preventing chronic disease: a vital investment. Geneva: World Health Organization; 2005http:// www.who.int/chp/chronic_disease_report/full_report.pdf. Accessed December 15, 2011
4. World Health Organization. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008http://www. who.int/healthinfoglobal_burden_disease/2004_report_update/en/ index.html. Accessed December 15, 2011
5. US General Accounting Office. GAO report number GAO-03- 829: technology transfer: NIH-private sector partnership in the development of Taxol. June 6, 2003. http://www.gao.gov/assets/ 240/238442.html
6. Agency wants to end AIDS drug monopoly. New York Times. May 29, 1991http://www.nytimes.com/1991/05/29/us/agencywants- to-end-aids-drug-monopoly.html. Accessed March 1, 2012
7. National Institute of Mental Health. Treatment development: the past 50 years. December14, 2011http://www.nimh.nih.gov/ about/director/2011/treatment-development-the-past-50-years.sht ml. Accessed March 1, 2012
8. National Institutes of Health. Definitions under subsection 1 (research objectives), section I (funding opportunity description), part II (full text of announcement), of RFA-RM-07-007: Institutional Clinical and Translational Science Award (U54), March 2007 http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-07- 007.html. Accessed January 4, 2013
9. Gillum L,Gouveia C, Dorsey E, et al.NIH disease funding levels and burden of disease. PLoS One. 2011;6(2):e16837www.plosone.org/ article/info%3Adoi%2F10.1371%2Fjournal.pone.0016837#s5
10. Harris G. Federal research center will help develop medicines. New York Times. January 22, 2011http://www.nytimes.com/2011/01/ 23/health/policy/23drug.html? pagewanted1/4all. Accessed December 15, 2011
11. Committee on the NIH Research Priority-Setting Process, Institute of Medicine. Scientific opportunities and public needs: improving priority setting and public input at the NIH. National Academy Press; 1998http://www.nap.edu, accessed March 1, 2008
12. National Research Council. Scientific Opportunities and Public Needs: Improving Priority Setting and Public Input at the National Institutes of Health. Washington, DC: The National Academies Press; 1998
13. Wang S. Sanofi's Zerhouni on translational research: no simple solution. Wall Street Journal Health Blog. May 20, 2011http:// blogs.wsj.com/health/2011/05/20/sanofis-zerhouni-on-translationalresearch- no-simple-solution/. Accessed December 15, 2011
14. Adis database. http://www.springer.com/adis/databases/r%26dthin sight?SGWID1/40-1749114-0-0-0.